First human trial that could permanently lower cholesterol In 2022, a New Zealand woman, suffering from heart disease, was the first person to receive a gene-editing treatment to permanently lower her cholesterol level. In this way, the researchers work so that this treatment can serve all people who suffer from high cholesterol. This breakthrough is designed to permanently turn off a gene in the liver that controls the production of PCSK9, a protein that prevents the removal of excess cholesterol from the body.
For its development, the test was carried out with monkeys , and it allowed reducing their cholesterol levels by 70% in just two weeks and kept the levels low for at least two years. CRISPR technology is sometimes south africa phone number list used to cut DNA; Verve's treatment simply changes a single letter in the PCSK9 gene to another. Therefore, this treatment is based on a more precise approach changing one DNA base for another, being a safer method because in this way they reduce the chances of cutting an important gene by mistake and avoid problems when DNA repairs itself.
The future of gene editing technology This technology could mean a breakthrough in the field of health and in the treatment of diseases by allowing scientists to insert pieces of DNA into a genome and replace disease-causing genes. At the moment, CRISPR treatments are in the experimental phases to verify their safety when applied to humans. However, if it works as well as it did on the first New Zealand patient, the treatment could save countless lives, permanently lowering cholesterol and the risk of heart attack.According to these historians of science, it is necessary to reformulate the question in this way in order to be able to reinterpret a gap in the historical records "as testimony of a certain action." Because forgetting, like remembering, is an active exercise.